Baseline characteristics of CAD patients enrolled for platelet aggregation test and surface expression of CXCR4 and ACKR3/CXCR7
| CAD patients’ characteristics . | CAD (n = 230) . |
|---|---|
| Age (mean ± SD) | 67.1 (± 11.9) |
| Male gender | 170 (73.9%) |
| LVEF % at admission (mean ± SD) | 50.6 (± 11.0) |
| Cardiovascular risk factors | |
| Arterial hypertension | 200 (87.0%) |
| Hyperlipidemia | 134 (58.3%) |
| Diabetes mellitus type 2 | 60 (26.1%) |
| Smoking | 104 (45.2%) |
| Medication on admission | |
| ASA | 123 (53.5%) |
| Clopidogrel | 27 (11.7%) |
| Prasugrel | 4 (1.7%) |
| Ticagrelor | 10 (4.3%) |
| ACE inhibitors | 90 (39.1%) |
| ARBs | 38 (16.5%) |
| β blockers | 117 (50.9%) |
| Ca-channel inhibitors | 45 (19.6%) |
| Diuretics | 74 (32.1%) |
| Statins | 99 (43.0%) |
| Reason of admission/clinical diagnosis | |
| ACS | 142 (61.7%) |
| CCS | 88 (38.3%) |
| Plasma lipid profile | |
| Total cholesterol (mg/dl) | 177.1 (± 46.5) |
| CAD patients’ characteristics . | CAD (n = 230) . |
|---|---|
| Age (mean ± SD) | 67.1 (± 11.9) |
| Male gender | 170 (73.9%) |
| LVEF % at admission (mean ± SD) | 50.6 (± 11.0) |
| Cardiovascular risk factors | |
| Arterial hypertension | 200 (87.0%) |
| Hyperlipidemia | 134 (58.3%) |
| Diabetes mellitus type 2 | 60 (26.1%) |
| Smoking | 104 (45.2%) |
| Medication on admission | |
| ASA | 123 (53.5%) |
| Clopidogrel | 27 (11.7%) |
| Prasugrel | 4 (1.7%) |
| Ticagrelor | 10 (4.3%) |
| ACE inhibitors | 90 (39.1%) |
| ARBs | 38 (16.5%) |
| β blockers | 117 (50.9%) |
| Ca-channel inhibitors | 45 (19.6%) |
| Diuretics | 74 (32.1%) |
| Statins | 99 (43.0%) |
| Reason of admission/clinical diagnosis | |
| ACS | 142 (61.7%) |
| CCS | 88 (38.3%) |
| Plasma lipid profile | |
| Total cholesterol (mg/dl) | 177.1 (± 46.5) |
We included n = 230 consecutive patients with symptomatic CAD to analyze platelet ACKR3/CXCR7 surface expression and aggregation response to ADP and TRAP in whole blood samples.